Process analytics for purification of monoclonal antibodies

Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences

Volumn 848, Issue 1, 2007, Pages 79-87

  Flatman, Stephen ^a   Alam, Imtiaz ^a   Gerard, Jeffery ^a   Mussa, Nesredin ^a  

^a LONZA AG   (Switzerland)

Author keywords

Analytical methods; Antibodies; Process analytical technology; Purification

Indexed keywords

BIOASSAY; DRUG PRODUCTS; ELECTROPHORESIS; LIQUID CHROMATOGRAPHY; PURIFICATION;

ANALYTICAL METHODS; IMMUNOASSAYS; PROCESS ANALYTICAL TECHNOLOGY;

MONOCLONAL ANTIBODIES;

CELL DNA; CELL PROTEIN; MONOCLONAL ANTIBODY; PROTEIN A;

ANALYTIC METHOD; BINDING ASSAY; CELL ASSAY; CIRCULAR DICHROISM; DIFFERENTIAL SCANNING CALORIMETRY; DRUG ACTIVITY; DRUG DETERMINATION; DRUG FORMULATION; DRUG IDENTIFICATION; DRUG POTENCY; DRUG PURIFICATION; DRUG PURITY; ELECTROPHORESIS; ENZYME LINKED IMMUNOSORBENT ASSAY; FLOW MEASUREMENT; GAS CHROMATOGRAPHY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HOST CELL; IMMUNOASSAY; INFRARED SPECTROSCOPY; ION PAIR CHROMATOGRAPHY; LIGHT SCATTERING; MASS SPECTROMETRY; PHYSICAL CHEMISTRY; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RAMAN SPECTROMETRY; REVERSED PHASE HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; REVIEW; SEPARATION TECHNIQUE; ULTRACENTRIFUGATION; WESTERN BLOTTING;

ANIMALS; ANTIBODIES, MONOCLONAL; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; ELECTROPHORESIS; ENZYME-LINKED IMMUNOSORBENT ASSAY; HUMANS;

EID: 33847631290     PISSN: 15700232     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jchromb.2006.11.018     Document Type: Review

References (25)

1. Food and Drug Administration, Guidance for Industry, PAT-A Framework for Innovative Pharmaceutical Development, Manufacturing and Quality Assurance, 2004 (http://www.fda.gov/cder/guidance/published.html).
2. European Medicines Agency, Mandate for Joint Team of QWP/Ad Hoc GMP Inspectors Group for Process Analytical Technology, Ref.: EMEA/35146/04, 2004.
3. Westermeier R. Electrophoresis in Practice. fourth ed. (2005), Wiley-VCH Verlag GmbH & Co., KGaA, Weinheim
4. Eby M.J. Biotechnology 7 (1989) 903
5. Janini G., Saptharishi N., Waselus M., and Soman G. Electrophoresis 23 (2002) 1605
6. Mussa N.A., Cheung K.Y., Alam I.A., and Flatman S. Genet. Eng. News 23 (2003) 50
7. Mant C.T., and Hodges R.S. J. Liquid Chromatogr. 12 (1989) 139
8. Roitsch C., and Barnes M. Immunol. Methods III (1985) 85
9. Cromwell M.E., and Jacobson H.E. AAPS J. 8 (2006) E572
10. Ejima D., Yumioka R., Arakawa T., and Tsumoto K. J. Chromatogr. A 1094 (2005) 49
11. Bongers J., Cummings J.L., Ebert M.E., Federici M.M., Gledhill L., Gulati D., Hilliard G.M., Jones B.H., Lee K.R., Mozdzanowski J., Naimoli M., and Burman S. J. Pharm. Anal. 21 (2000) 1099
12. Folta-Stogniew E., and Williams K.R. J. Biomol. Techn. 10 (1999) 51
13. Pelton J.T., and Lean L.R. Anal. Biochem. 277 (2000) 167
14. Matheus S., Mahler H.C., and Friess W. Pharm. Res. 23 (2006) 1617
15. Wang Q., Tolkach A., and Kulozik U. J. Agric. Food. Chem. 54 (2006) 6501
16. WHO Guideline Requirements for Use of Animal Cells as in Vitro Substrates for the Production of Biologicals. Requirements for Biological Substances No. 50, 1997.
17. Per S.R., Aversa C.R., and Sito A.F. Dev. Biol. Stand. 71 (1990) 173
18. Kung V.T., Panfili P.R., Sheldon E.L., King R.S., Nagainis P.A., Gomez B., Ross D.A., Briggs J., and Zuk R.F. Anal. Biochem. 187 (1990) 220
19. Gijsbers L., Koel B., Weggeman M., Goudsmit J., Havenga M., and Marzio G. Hum. Gene Ther. 16 (2005) 393
20. Wierenga D.E., Cogan J., and Petriccaini J.C. Biologicals 22 (1995) 221
21. CPMP, Position statement on the use of tumourigenic cells of human origin for the production of biological and biotechnological medicinal products, 2001.
22. Eaton L.C. J. Chromatogr. A 705 (1995) 105
23. Hammerl P., Hartl A., and Thalhamer J. J. Immunol. Methods 160 (1993) 155
24. Lou J., Zhou J., Zou W., and Shen P. J. Biochem. 130 (2001) 553
25. Cooper M.A. Drug Disc. World Summer (2006) 68